Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + NK cell immunotherapy
- Development stage
- Unknown
- Lead developer
- Fuda Cancer Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Trastuzumab + NK cell immunotherapy is a combination treatment regimen being evaluated by Fuda Cancer Hospital in Guangzhou for the treatment of HER2-positive recurrent breast cancer. The therapy utilizes autologous natural killer (NK) cells, which are harvested from the patient's peripheral blood and expanded ex vivo into billions of 'Highly Active Natural Killer' (HANK) cells using specific cytokines. These activated NK cells are then reinfused into the patient in combination with trastuzumab, a monoclonal antibody that targets the HER2 protein overexpressed in certain breast cancers. The mechanism of action involves the synergistic effect of trastuzumab-mediated inhibition of HER2 signaling and the NK cells' ability to execute antibody-dependent cellular cytotoxicity (ADCC) and direct cytotoxic lysis of cancer cells. This investigational approach is currently in Phase 1/2 clinical testing to assess safety and efficacy in patients who have failed prior therapies.
- Brand names
- HANK
- Other names
- NK immunotherapyHANK immunotherapyTrastuzumab plus natural killer immunotherapyAutologous NK cell therapy
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab + NK cell immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + NK cell immunotherapy.